Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INE 963

X
Drug Profile

INE 963

Alternative Names: INE-963; MMV-1582617; NVP-INE963

Latest Information Update: 15 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antimalarials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Falciparum malaria
  • Phase I Malaria

Most Recent Events

  • 02 Mar 2024 Novartis Pharmaceuticals completes a phase I trial in Malaria (In volunteers, Monotherapy, Combination therapy) in United Kingdom (PO) (ISRCTN17232240)
  • 23 Jan 2024 Phase-II clinical trials in Falciparum malaria (Combination therapy, In adolescents, In adults, In children, In the elderly) in Kenya, Ghana, Ivory Coast (PO) (NCT05750628)
  • 23 Jan 2024 Phase-II clinical trials in Falciparum malaria (In adolescents, In adults, In children, In the elderly, Monotherapy) in Ghana, Ghana, Ivory Coast, Kenya (PO) (NCT05750628)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top